Form 4: Singular Genomics CEO Andrew Spaventa Executes Stock Transactions Following RSU Vesting
SEC Form 4 Filing
Singular Genomics CEO Andrew Spaventa acquired and disposed of company stock following the vesting of restricted stock units, including sales to cover tax obligations and gifts to a living trust.
Summary
- Singular Genomics CEO Andrew Spaventa received 486 shares of common stock on December 15, 2024, upon the vesting of restricted stock units (RSUs).
- On December 16, 2024, Mr. Spaventa sold 180 shares at a weighted average price of $20.1617 per share to cover tax obligations related to the RSU vesting.
- Also on December 16, 2024, Mr. Spaventa gifted 306 shares to The Andrew K. Spaventa Living Trust dated April 9, 2014.
- Following these transactions, Mr. Spaventa directly owns 631 shares and indirectly owns 141,793 shares through The Andrew K. Spaventa Living Trust and 85 shares through Axon Holdings, LLC.
- The RSUs vest in 16 equal quarterly installments over four years, starting from March 15, 2023.
Sentiment
Score: 5
Explanation: The document reflects routine transactions related to executive compensation and does not indicate any positive or negative sentiment.
Industry Context
This is a routine filing related to executive compensation and does not indicate any specific trend in the genomics industry.
Comparison to Industry Standards
- Stock transactions by executives are common in publicly traded companies, particularly following the vesting of equity awards.
- The sale of shares to cover tax obligations is a standard practice.
- The gifting of shares to a living trust is a common estate planning strategy.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are related to executive compensation and do not indicate a change in the company's fundamentals.
Key Dates
| Date | Description |
|---|---|
| 2014-04-09 | Date of The Andrew K. Spaventa Living Trust. |
| 2023-03-15 | Start date for RSU vesting schedule. |
| 2024-12-15 | Date of RSU vesting and acquisition of 486 shares. |
| 2024-12-16 | Date of stock sales and gifts. |
| 2024-12-17 | Date of filing of the SEC Form 4. |
Keywords
Singular Genomics, Andrew Spaventa, stock transactions, restricted stock units, RSU, insider trading, beneficial ownership, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.